World's Best Scientists 2026 revealed!
Award Badge
Medicine
Canada
2023

D-Index & Metrics

Medicine

D-Index
143
Citations
100557
World Ranking
1480
National Ranking
46

Mark Levine publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Mark Levine sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 610 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 688 publications — 80th percentile

80% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Mark Levine D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Mark Levine sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 399 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 143 D-Index — 93rd percentile

93% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Research.com Recognitions

  • 2023 - Research.com Medicine in Canada Leader Award
  • 2014 - Fellow of the American Association for the Advancement of Science (AAAS)

Overview

Mark Levine is affiliated with McMaster University in Canada. Their research contributions primarily focus on the fields of Medicine and Biochemistry, Genetics and Molecular Biology, with significant work in oncology and related subfields.

The main subfields of study that characterize Levine's research include:

  • Oncology
  • Cancer Research
  • Pulmonary and Respiratory Medicine
  • Pathology and Forensic Medicine
  • Surgery

The scientist's research topics cover a range of cancer-related themes, including:

  • Breast Cancer Treatment Studies
  • Cancer survivorship and care
  • Global Cancer Incidence and Screening
  • Vitamin C and Antioxidants Research
  • Cancer Treatment and Pharmacology
  • Breast Lesions and Carcinomas
  • Venous Thromboembolism Diagnosis and Management

Levine has published extensively in several prominent medical and oncology journals. The frequent venues for their publications include:

  • Journal of Clinical Oncology
  • The Lancet
  • UNC Libraries
  • New England Journal of Medicine
  • JAMA Oncology

Some recent papers authored in collaboration with various researchers illustrate the scope and focus of Levine's work:

  • "Anthracycline-containing and taxane-containing chemotherapy for early-stage operable breast cancer: a patient-level meta-analysis of 100,800 women from 86 randomised trials," 2023, The Lancet
  • "Omitting Radiotherapy after Breast-Conserving Surgery in Luminal A Breast Cancer," 2023, New England Journal of Medicine
  • "Developing a Data and Analytics Platform to Enable a Breast Cancer Learning Health System at a Regional Cancer Center," 2023, JCO Clinical Cancer Informatics
  • "Metformin in Combination With Chemoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer," 2021, JAMA Oncology
  • "Treatment of cancer-associated venous thromboembolism: 12-month outcomes of the placebo versus rivaroxaban randomization of the SELECT-D Trial (SELECT-D: 12m)," 2020, Journal of Thrombosis and Haemostasis

Levine collaborates frequently with other researchers in related oncology and clinical fields. Noted frequent co-authors include:

  • Sameer Parpia
  • Gregory R. Pond
  • Timothy J. Whelan
  • Kathleen I. Pritchard
  • Lois E. Shepherd

In recognition of their scientific contributions, Levine has been awarded the title of Fellow of the American Association for the Advancement of Science (AAAS) in 2014.

Best Publications

  • Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials

    O. Abe;R. Abe;K. Enomoto;K. Kikuchi

  • Evidence-Based Medicine: A New Approach to Teaching the Practice of Medicine

    Gordon Guyatt;John Cairns;David Churchill;Deborah Cook

  • Heparin-Induced Thrombocytopenia in Patients Treated with Low-Molecular-Weight Heparin or Unfractionated Heparin

    Theodore E. Warkentin;Mark N. Levine;Jack Hirsh;Peter Horsewood

  • Low-Molecular-Weight Heparin versus a Coumarin for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer

    Agnes Y.Y. Lee;Mark N. Levine;Ross I. Baker;Chris Bowden

  • Vitamin C as an Antioxidant: Evaluation of Its Role in Disease Prevention

    Sebastian J. Padayatty;Arie Katz;Yaohui Wang;Peter Eck

  • Long-Term Results of Hypofractionated Radiation Therapy for Breast Cancer

    Timothy J Whelan;Jean-Philippe Pignol;Mark N Levine;Jim A Julian

  • A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis.

    Mark Levine;Michael Gent;Jack Hirsh;Jacques Leclerc

  • 2000 Update of Recommendations for the Use of Hematopoietic Colony-Stimulating Factors: Evidence-Based, Clinical Practice Guidelines*

    Thomas J. Smith;Howard Ozer;Langdon L. Miller;Charles A. Schiffer

  • American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer

    Gary H. Lyman;Alok A. Khorana;Anna Falanga;Daniel Clarke-Pearson

  • Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update

    Nigel S Key;Alok A Khorana;Nicole M Kuderer;Kari Bohlke

  • Regional Nodal Irradiation in Early-Stage Breast Cancer

    Timothy J. Whelan;Ivo A. Olivotto;Wendy R. Parulekar;Ida Ackerman

  • Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)

    Annie M. Young;Andrea Marshall;Jenny Thirlwall;Oliver Chapman

  • Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014

    Gary H. Lyman;Gary H. Lyman;Kari Bohlke;Alok A. Khorana;Nicole M. Kuderer

  • Hemorrhagic Complications of Anticoagulant Treatment

    Mark N. Levine;Gary Raskob;Seth Landefeld;Clive Kearon

  • Hemorrhagic Complications of Anticoagulant and Thrombolytic Treatment: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)

    Sam Schulman;Rebecca J. Beyth;Clive Kearon;Mark N. Levine

  • Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.

    M. N. Levine;V. H. Bramwell;K. I. Pritchard;B. D. Norris

  • Venous Thromboembolism and Cancer: Risks and Outcomes

    Agnes Y.Y. Lee;Mark N. Levine

  • Low molecular weight heparin, therapy with dalteparin, and survival in advanced cancer: the fragmin advanced malignancy outcome study (FAMOUS).

    Ajay K. Kakkar;Mark N. Levine;Zbigniew Kadziola;Nicholas R. Lemoine

  • New concepts in the biology and biochemistry of ascorbic acid.

    Mark Levine

  • A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis

    Arlan H. Mintz;John Kestle;Michel P. Rathbone;Laurie Gaspar

Frequent Co-Authors

Jim A. Julian
Jim A. Julian McMaster University
Timothy J. Whelan
Timothy J. Whelan McMaster University
Kathleen I. Pritchard
Kathleen I. Pritchard University of Toronto
Jack Hirsh
Jack Hirsh McMaster University
Michael Gent
Michael Gent McMaster University
Gregory R. Pond
Gregory R. Pond McMaster University
Amiram Gafni
Amiram Gafni McMaster University
Alexander G.G. Turpie
Alexander G.G. Turpie McMaster University
Ajay K. Kakkar
Ajay K. Kakkar University College London
Jeffrey S. Ginsberg
Jeffrey S. Ginsberg McMaster University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

The pathway to a career in medicine doesn’t only go through traditional medical school. There are a variety of related fields and flexible online degree options that can lead to dynamic roles in healthcare. Exploring online health administration programs is a great option for those interested in the organizational side of healthcare and leadership roles in hospitals or clinics.

For registered nurses, advancing through asn to np bridge programs can smoothly transition you to a nurse practitioner position. These bridging programs are designed for working professionals and often offer flexible online coursework.

Those passionate about preventative care and healthy living may consider online nutrition degree programs, which prepare graduates for roles in dietetics, wellness coaching, and community health.

If you’re seeking advanced management training in healthcare, consider programs from the cahme accredited online mha programs list. These programs hold high recognition and can boost your qualifications for executive roles in the healthcare sector.

Best Scientists Citing Mark Levine

Trending Scientists

Recently Published Articles